Published online before print June 6, 2005, doi: 10.1161/CIRCULATIONAHA.104.521625
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2005;111:3087-3094.)
© 2005 American Heart Association, Inc.
Heart Failure |
Aldosterone Synthase Inhibitor Ameliorates Angiotensin II–Induced Organ Damage
From the Medical Faculty of the Charité (A.F., E.S., G.H., N.A.-S., R.D., M.W., S.M., F.C.L., D.N.M.), HELIOS Klinikum-Berlin, Franz Volhard Clinic, Berlin, Germany; Max Delbrück Center for Molecular Medicine (F.C.L., D.N.M.), Berlin-Buch, Germany; Medical School of Hannover (S.R.), Hannover, Germany; Novartis Institutes for Biomedical Research (A.Y.J., R.L.W.), East Hanover, NJ; Centre Hospitalier Universitaire Vaudois (J.N.), Hypertension Division, Lausanne, Switzerland; and University of Heidelberg (C.M.-G.), Institute of Pharmacology, Heidelberg, Germany.
Correspondence to Anette Fiebeler, MD, Franz Volhard Clinic, Wiltberg Strasse 50, 13125 Berlin, Germany. E-mail fiebeler{at}fvk-berlin.de
Received November 15, 2004; revision received January 20, 2005; accepted February 18, 2005.
Background— Aldosterone and angiotensin (Ang) II both may cause organ damage. Circulating aldosterone is produced in the adrenals; however, local cardiac synthesis has been reported. Aldosterone concentrations depend on the activity of aldosterone synthase (CYP11B2). We tested the hypothesis that reducing aldosterone by inhibiting CYP11B2 or by adrenalectomy (ADX) may ameliorate organ damage. Furthermore, we investigated how much local cardiac aldosterone originates from the adrenal gland.
Methods and Results— We investigated the effect of the CYP11B2 inhibitor FAD286, losartan, and the consequences of ADX in transgenic rats overexpressing both the human renin and angiotensinogen genes (dTGR). dTGR-ADX received dexamethasone and 1% salt. Dexamethasone-treated dTGR-salt served as a control group in the ADX protocol. Untreated dTGR developed hypertension and cardiac and renal damage and had a 40% mortality rate (5/13) at 7 weeks. FAD286 reduced mortality to 10% (1/10) and ameliorated cardiac hypertrophy, albuminuria, cell infiltration, and matrix deposition in the heart and kidney. FAD286 had no effect on blood pressure at weeks 5 and 6 but slightly reduced blood pressure at week7 (177±6 mm Hg in dTGR+FAD286 and 200±5 mm Hg in dTGR). Losartan normalized blood pressure during the entire study. Circulating and cardiac aldosterone levels were reduced in FAD286 or losartan-treated dTGR. ADX combined with dexamethasone and salt treatment decreased circulating and cardiac aldosterone to barely detectable levels. At week 7, ADX-dTGR-dexamethasone-salt had a 22% mortality rate compared with 73% in dTGR-dexamethasone-salt. Both groups were similarly hypertensive (190±9 and 187±4 mm Hg). In contrast, cardiac hypertrophy index, albuminuria, cell infiltration, and matrix deposition were significantly reduced after ADX (P<0.05).
Conclusions— Aldosterone plays a key role in the pathogenesis of Ang II–induced organ damage. Both FAD286 and ADX reduced circulating and cardiac aldosterone levels. The present results show that aldosterone produced in the adrenals is the main source of cardiac aldosterone.
Key Words: aldosterone • angiotensin • heart failure • renin • inflammation
Related Article:
Circulation 2005 111: 3015.
This article has been cited by other articles:
 |
|
 |
|
  J. Peters, T. Schluter, T. Riegel, B. S. Peters, A. Beineke, U. Maschke, N. Hosten, J. J. Mullins, and R. Rettig Lack of cardiac fibrosis in a new model of high prorenin hyperaldosteronism Am J Physiol Heart Circ Physiol, November 1, 2009; 297(5): H1845 - H1852. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Geerling and A. D. Loewy Aldosterone in the brain Am J Physiol Renal Physiol, September 1, 2009; 297(3): F559 - F576. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Pitt RAAS inhibition/blockade in patients with cardiovascular disease: implications of recent large-scale randomised trials for clinical practice Heart, August 1, 2009; 95(15): 1205 - 1208. [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Luther, Z. Wang, J. Ma, N. Makhanova, H.-S. Kim, and N. J. Brown Endogenous Aldosterone Contributes to Acute Angiotensin II-Stimulated Plasminogen Activator Inhibitor-1 and Preproendothelin-1 Expression in Heart But Not Aorta Endocrinology, May 1, 2009; 150(5): 2229 - 2236. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Klotz, D. Burkhoff, I. M. Garrelds, F. Boomsma, and A.H.J. Danser The impact of left ventricular assist device-induced left ventricular unloading on the myocardial renin-angiotensin-aldosterone system: therapeutic consequences? Eur. Heart J., April 1, 2009; 30(7): 805 - 812. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. S. Huang, R. A. White, A. Y. Jeng, and F. H. H. Leenen Role of central nervous system aldosterone synthase and mineralocorticoid receptors in salt-induced hypertension in Dahl salt-sensitive rats Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2009; 296(4): R994 - R1000. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Di Zhang, A. N. D. Cat, C. Soukaseum, B. Escoubet, A. Cherfa, S. Messaoudi, C. Delcayre, J.-L. Samuel, and F. Jaisser Cross-Talk Between Mineralocorticoid and Angiotensin II Signaling for Cardiac Remodeling Hypertension, December 1, 2008; 52(6): 1060 - 1067. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Klanke, N. Cordasic, A. Hartner, R. E. Schmieder, R. Veelken, and K. F. Hilgers Blood pressure versus direct mineralocorticoid effects on kidney inflammation and fibrosis in DOCA-salt hypertension Nephrol. Dial. Transplant., November 1, 2008; 23(11): 3456 - 3463. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Karagiannis, K. Tziomalos, A. I Kakafika, V. G Athyros, F. Harsoulis, and D. P Mikhailidis Medical treatment as an alternative to adrenalectomy in patients with aldosterone-producing adenomas Endocr. Relat. Cancer, September 1, 2008; 15(3): 693 - 700. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Mulder, V. Mellin, J. Favre, M. Vercauteren, I. Remy-Jouet, C. Monteil, V. Richard, S. Renet, J. P. Henry, A. Y. Jeng, et al. Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone Eur. Heart J., September 1, 2008; 29(17): 2171 - 2179. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. S. Huang, R. A. White, M. Ahmad, A. Y. Jeng, and F. H. H. Leenen Central infusion of aldosterone synthase inhibitor prevents sympathetic hyperactivity and hypertension by central Na+ in Wistar rats Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2008; 295(1): R166 - R172. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. M. Siragy and C. Xue Local renal aldosterone production induces inflammation and matrix formation in kidneys of diabetic rats Exp Physiol, July 1, 2008; 93(7): 817 - 824. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Yu, S.-G. Wei, Z.-H. Zhang, E. Gomez-Sanchez, R. M. Weiss, and R. B. Felder Does Aldosterone Upregulate the Brain Renin-Angiotensin System in Rats With Heart Failure? Hypertension, March 1, 2008; 51(3): 727 - 733. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z.-H. Zhang, Y. Yu, Y.-M. Kang, S.-G. Wei, and R. B. Felder Aldosterone acts centrally to increase brain renin-angiotensin system activity and oxidative stress in normal rats Am J Physiol Heart Circ Physiol, February 1, 2008; 294(2): H1067 - H1074. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. J. Brown Aldosterone and Vascular Inflammation Hypertension, February 1, 2008; 51(2): 161 - 167. [Full Text] [PDF]
|
|
|
|
|
|
M. Minnaard-Huiban, J. M. A. Emmen, L. Roumen, I. P. E. Beugels, G. M. S. Cohuet, H. van Essen, E. Ruijters, K. Pieterse, P. A. J. Hilbers, H. C. J. Ottenheijm, et al. Fadrozole Reverses Cardiac Fibrosis in Spontaneously Hypertensive Heart Failure Rats: Discordant Enantioselectivity Versus Reduction of Plasma Aldosterone Endocrinology, January 1, 2008; 149(1): 28 - 31. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. N Muller Mechanisms of hypertension-induced target organ damage Journal of Renin-Angiotensin-Aldosterone System, September 1, 2007; 8(3): 148 - 150. [PDF]
|
|
|
|
 |
|
 N. Henke, R. Schmidt-Ullrich, R. Dechend, J.-K. Park, F. Qadri, M. Wellner, M. Obst, V. Gross, R. Dietz, F. C. Luft, et al. Vascular Endothelial Cell Specific NF-{kappa}B Suppression Attenuates Hypertension-Induced Renal Damage Circ. Res., August 3, 2007; 101(3): 268 - 276. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Grossmann, A. W. Krug, R. Freudinger, S. Mildenberger, K. Voelker, and M. Gekle Aldosterone-induced EGFR expression: interaction between the human mineralocorticoid receptor and the human EGFR promoter Am J Physiol Endocrinol Metab, June 1, 2007; 292(6): E1790 - E1800. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-K. Park, R. Fischer, R. Dechend, E. Shagdarsuren, A. Gapeljuk, M. Wellner, S. Meiners, P. Gratze, N. Al-Saadi, S. Feldt, et al. p38 Mitogen-Activated Protein Kinase Inhibition Ameliorates Angiotensin II-Induced Target Organ Damage Hypertension, March 1, 2007; 49(3): 481 - 489. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Wenxia Chai, Y. M Hoedemaekers, R. H. van Schaik, M. van Fessem, I. M Garrelds, J. J Saris, D. Dooijes, F. J ten Cate, M. M. Kofflard, and A. J. Danser Cardiac aldosterone in subjects with hypertrophic cardiomyopathy Journal of Renin-Angiotensin-Aldosterone System, December 1, 2006; 7(4): 225 - 230. [Abstract] [PDF]
|
|
|
|
 |
|
 D. Hilfiker-Kleiner, U. Landmesser, and H. Drexler Molecular Mechanisms in Heart Failure: Focus on Cardiac Hypertrophy, Inflammation, Angiogenesis, and Apoptosis J. Am. Coll. Cardiol., October 27, 2006; 48(9_Suppl_A): A56 - A66. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. S. Huang, W. J. Cheung, H. Wang, J. Tan, R. A. White, and F. H. H. Leenen Activation of brain renin-angiotensin-aldosterone system by central sodium in Wistar rats Am J Physiol Heart Circ Physiol, September 1, 2006; 291(3): H1109 - H1117. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Hunyady and K. J. Catt Pleiotropic AT1 Receptor Signaling Pathways Mediating Physiological and Pathogenic Actions of Angiotensin II Mol. Endocrinol., May 1, 2006; 20(5): 953 - 970. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Chai, I. M. Garrelds, R. de Vries, and A.H. Jan Danser Cardioprotective Effects of Eplerenone in the Rat Heart: Interaction With Locally Synthesized or Blood-Derived Aldosterone? Hypertension, April 1, 2006; 47(4): 665 - 670. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Miyata, M. Rahman, T. Shokoji, Y. Nagai, G.-X. Zhang, G.-P. Sun, S. Kimura, T. Yukimura, H. Kiyomoto, M. Kohno, et al. Aldosterone Stimulates Reactive Oxygen Species Production through Activation of NADPH Oxidase in Rat Mesangial Cells J. Am. Soc. Nephrol., October 1, 2005; 16(10): 2906 - 2912. [Abstract] [Full Text] [PDF]
|
|